APNmAb 005
Alternative Names: Anti-tau monoclonal antibody - APRINOIA Therapeutics; APN-005; APN-mAb-005Latest Information Update: 28 Jun 2025
At a glance
- Originator APRINOIA Therapeutics
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tauopathies
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Tauopathies(In volunteers) in USA (IV, Infusion)
- 16 Jul 2023 Safety and pharmacodynamics data from a preclicial trial in Alzheimer’s disease presented at theAlzheimer's Association International Conference 2023 (AAIC-2023)
- 01 May 2022 Phase-I clinical trials in Tauopathies (In volunteers) in USA (Parenteral) (NCT05344989)